STADA Arzneimittel AG (STADA) and Xbrane Biopharma AB jointly present their new product Ximluci®, a ranibizumab biosimilar, for the market launch in Germany. Ximluci® aims to offer ophthalmologists and their patients a cost-effective alternative to the reference product and to provide a universal option for the treatment of certain retinal disorders caused by damage to the retina and particularly the macula (nAMD, DME, PDR, RVO and CNV) 1). As a biosimilar, Ximluci® offers comparable efficacy, safety and immunogenicity profile to the reference product2.

Ximluci has already started shipping in some European countries such as Germany, while others are currently preparing for launch. For the launch in Germany, the product was presented at the congress of the Ophthalmological Academy Germany (AAD) in March 2023 in Düsseldorf. STADA was represented with a stand on Ximluci® and several information materials, such as a product trailer and brochures for trade visitors and patients in the industrial exhibition.

The event was used to discuss the new treatment option with numerous interested physicians. Ximluci® is the first biosimilar developed as part of a strategic partnership between STADA and Xbrane entered in July 2018. According to the collaboration agreement, both partners are responsible for the development and manufacturing of the product, which takes place entirely in Europe, while STADA holds the market approvals and commercial rights to the product.